Tirzepatide: Frequently Asked Questions | Tirzepatide
What is tirzepatide?
Tirzepatide is an FDA-approved prescription drug — a 39-amino-acid synthetic peptide that activates both the GIP and GLP-1 receptors (two gut-hormone receptors involved in insulin release and appetite regulation). It is the first and only approved dual GIP/GLP-1 receptor agonist. It is administered as a subcutaneous injection once weekly [1][6].
How does tirzepatide work?
Tirzepatide activates both the GIP receptor and the GLP-1 receptor simultaneously. Engaging both receptors enhances glucose-dependent insulin secretion, suppresses glucagon (a hormone that raises blood glucose), slows gastric emptying, and reduces appetite centrally. The dual mechanism produces larger glycaemic and weight reductions in trials than GLP-1 receptor agonism alone [1][12].
What does tirzepatide do in the body?
Tirzepatide stimulates insulin secretion in a glucose-dependent manner (so insulin release is tied to blood glucose levels), suppresses glucagon, slows the rate at which the stomach empties into the intestine, and dampens appetite signals in the brain. GIP and GLP-1 receptors are expressed in the liver, muscle, adipose tissue, heart, kidney, and central nervous system — producing effects across multiple organ systems beyond the pancreas [11].
What is tirzepatide used for?
Three FDA-approved indications: (1) type 2 diabetes mellitus as an adjunct to diet and exercise (approved May 2022); (2) chronic weight management in adults with BMI ≥30 or ≥27 with a weight-related condition (approved November 2023); and (3) moderate-to-severe obstructive sleep apnea in adults with obesity. It is not approved for type 1 diabetes [6].
Is tirzepatide a GLP-1?
Tirzepatide is not a selective GLP-1 receptor agonist — it is a dual GIP/GLP-1 receptor agonist. It activates both the GLP-1 receptor and the GIP receptor. This dual mechanism distinguishes it from the selective GLP-1 receptor agonist class that preceded it. The GIP component is the primary structural basis for tirzepatide's observed superiority over GLP-1-only agents in head-to-head trials [1][12].
Is tirzepatide a peptide?
Yes. Tirzepatide is a 39-amino-acid synthetic acylated peptide. Its backbone is derived from the native GIP hormone sequence, modified with a C20 fatty-diacid arm attached via a glutamic-acid linker to a lysine side chain. That fatty-acid modification confers albumin affinity, extending the half-life to approximately five days and enabling once-weekly dosing [1].
Is tirzepatide FDA approved?
Yes. Tirzepatide was first approved by the FDA in May 2022 for type 2 diabetes mellitus. A second approval for chronic weight management followed in November 2023. A third approval for moderate-to-severe obstructive sleep apnea in adults with obesity was subsequently granted. It is a prescription drug only and is not approved for type 1 diabetes or for use in children [6][28].
How long has tirzepatide been around?
The discovery paper for LY3298176 (the development code for tirzepatide) was published in 2018. Phase 1 trials in humans followed. The major phase 3 programmes (SURPASS for type 2 diabetes, SURMOUNT for obesity) ran from approximately 2019 to 2022. FDA approval came in May 2022. The molecule has approximately four years of post-approval real-world exposure as of 2026 [1][6].
How does tirzepatide work for weight loss?
Tirzepatide reduces weight primarily through reduced appetite and food intake, driven by dual GIP and GLP-1 receptor activation in the brain and gut. Slowed gastric emptying prolongs satiety after meals. In SURMOUNT-1, 79–91% of participants in exit interviews described reduced appetite — the 'quieting of food noise' — as a primary mechanism of their weight reduction. The central appetite effects operate independently of glucose-lowering [1][3].
How much weight can you lose on tirzepatide?
In SURMOUNT-1 (n=2,539, 72 weeks), mean weight change at the highest dose (15 mg) was -20.9% versus -3.1% with placebo. The 5 mg and 10 mg doses produced -15.0% and -19.5% respectively. In SURMOUNT-5 (head-to-head with semaglutide), the mean was -20.2% with tirzepatide versus -13.7% with semaglutide. These are population means; individual results vary [3][4].
How long does it take for tirzepatide to work?
In the SURMOUNT-1 trial, meaningful weight reductions were observable by week 12 and continued through week 72, with the greatest absolute change occurring during the first 36 weeks. In SURPASS-2, HbA1c reductions in type 2 diabetes were established at the first assessment point at 4 weeks. The dose-escalation phase (20 weeks from 2.5 mg to maintenance) means full maintenance-dose exposure begins at approximately week 20 [2][3].
What are the side effects of tirzepatide?
The most common adverse effects are gastrointestinal: nausea, diarrhoea, vomiting, constipation, and decreased appetite. These are dose-dependent and most frequent during dose escalation. A meta-analysis of 13 trials found the overall GI adverse-event risk approximately 2.9-fold above placebo. Other monitored signals include gallbladder/biliary disease (RR 1.97 in a 9-trial meta-analysis), hair loss (telogen effluvium), and injection site reactions [10][16][17].
What are the bad side effects of tirzepatide?
The most clinically significant side effects are: (1) gastrointestinal intolerance driving drug discontinuation; (2) gallbladder and biliary disease (significantly increased relative risk in meta-analysis) [10]; (3) hypoglycaemia when combined with insulin or sulfonylureas [6]; (4) lean-mass loss alongside fat mass (approximately 25% of weight lost is lean mass) [7]; and (5) weight regain if treatment is stopped. The boxed warning — thyroid C-cell tumours in rodents — has not been confirmed in humans.
Does tirzepatide cause diarrhea?
Diarrhoea is one of the most commonly reported gastrointestinal adverse events in the clinical trials and in community reports. A meta-analysis of tirzepatide-induced GI manifestations documented diarrhoea as part of the dose-dependent GI adverse-event cluster, most prominent during dose escalation. In community reports it is described by roughly 17–25% of users, typically peaking around day four post-injection [17][18].
Does tirzepatide lower blood pressure?
A dedicated 24-hour ambulatory blood pressure monitoring study (de la Cruz-Concepcion 2024) found significant reductions in 24-hour ambulatory systolic blood pressure in adults with BMI ≥27 treated with tirzepatide versus placebo. The SURPASS trials also documented blood pressure reductions as a secondary endpoint in type 2 diabetes. The mechanism likely involves both the weight reduction and direct vascular receptor effects [32].
Does tirzepatide protect the kidneys?
The SURPASS-4 kidney substudy found favourable effects on kidney outcomes — a slower decline in eGFR (estimated glomerular filtration rate, a measure of kidney filtering capacity) and reduced albuminuria (protein leakage into urine, a marker of kidney stress) — versus insulin glargine in adults with type 2 diabetes at high cardiovascular risk [5]. Whether similar protection extends to people without diabetes is not yet established in a dedicated trial.
What are the cardiovascular effects of tirzepatide?
SUMMIT (2025) showed tirzepatide reduced heart-failure events and improved functional status in adults with heart failure with preserved ejection fraction (HFpEF) and obesity [29]. SURPASS-CVOT reported cardiovascular outcomes data compared with dulaglutide in type 2 diabetes with established cardiovascular disease [31]. Blood pressure reductions have been demonstrated in ambulatory monitoring studies [32]. The cardiovascular outcomes programme represents the most recent expansion of the tirzepatide evidence base.
What is the difference between semaglutide and tirzepatide?
Semaglutide is a selective GLP-1 receptor agonist — it activates only the GLP-1 receptor. Tirzepatide activates both the GIP receptor and the GLP-1 receptor. Head-to-head trials in both type 2 diabetes (SURPASS-2) and obesity (SURMOUNT-5) show tirzepatide producing larger reductions in HbA1c and body weight than semaglutide at comparable or maximum tolerated doses [2][4]. GI tolerability profiles are similar in character — both cause nausea, vomiting, and diarrhoea — though the discontinuation-due-to-adverse-events rate is somewhat higher with tirzepatide [27].
Is tirzepatide better than semaglutide?
On the primary endpoints of both the SURPASS-2 (HbA1c reduction in type 2 diabetes) and SURMOUNT-5 (weight reduction in obesity) head-to-head trials, tirzepatide was statistically superior to semaglutide [2][4]. 'Better' depends on what matters in a given clinical context — the magnitude of weight and glycaemic benefit, individual tolerability, and the clinical indication all factor into a comparison that rests with a prescribing physician.
How long does tirzepatide stay in your system?
The elimination half-life of tirzepatide is approximately five days — conferred by the fatty-diacid arm that gives the molecule high albumin affinity and slow clearance. At that half-life, approximately 97% of a dose is cleared within roughly 25 days (five half-lives). The drug's pharmacological activity continues for the full week between once-weekly doses [1][6].
What is the half-life of tirzepatide?
Approximately five days. The fatty-diacid modification attached to the 39-amino-acid peptide backbone produces high albumin affinity, which dramatically slows renal and enzymatic clearance and extends the effective half-life to support once-weekly subcutaneous dosing. This is documented in the Phase 1 PK work and reflected in the prescribing information [1][6].
Why am I not losing weight on tirzepatide?
SURMOUNT-1 data show a dose-response gradient: the 5 mg dose produced -15.0% weight loss on average, which is less than the 15 mg dose's -20.9%. Plateaus are documented in both trial data and community reports, most commonly after the first three to six months. Metabolic adaptation, dietary drift, and stress are proposed contributors. Weight loss with tirzepatide is also population-mean data — individual responses vary substantially around that mean [3].